Current methods for early detection and treatment monitoring of cancer and other complex diseases often lack the sensitivity and breadth needed to capture the full spectrum of biological changes. Traditional approaches may not fully leverage the potential of multi-omics data, leading to delayed diagnoses and suboptimal treatment strategies.

PrognomiQ is developing multi-omics test products designed to improve early disease detection and treatment monitoring by integrating extensive proteomic, genomic, and metabolomic data. The company's approach involves generating proprietary proteomic data at high volumes and depths, which is then complemented with genomic, metabolomic, and other health data to discover innovative approaches to early disease detection. This multi-omics platform aims to provide unparalleled biological insights into the mechanisms of complex diseases, enabling earlier intervention and more effective therapy monitoring. By unlocking the potential of multi-omics data, PrognomiQ seeks to transform the landscape of disease detection and treatment, ultimately impacting millions of lives.

Proprietary multi-omics platform designed to generate proteomic, genomic, and metabolomic data at scale

Leveraging advanced proteomics to generate direct information of a person’s biological state, including state of disease

Integration of proteomic data with genomics and metabolomics for enhanced biological insights

Focus on identifying biomarkers for early disease detection and treatment monitoring

Utilizes the Proteograph product suite from Seer as part of its multi-omics platform

Application of data science and machine learning to analyze multi-omics data

The primary target audience includes healthcare providers, researchers, and pharmaceutical companies focused on early disease detection, treatment monitoring, and drug discovery for cancer and other complex diseases.